Trials in Massachusetts.
153 APOE4-relevant Alzheimer’s trials run in Massachusetts — 73 of them recruiting. Each one translated into plain English, with our read on what it means for an APOE4 carrier.
- Where
- Boston · Newton · Plymouth · Watertown · Springfield · Belmont · Waltham · Charlestown
- Recruiting
- 73 of 153
Non-carriers only, not for APOE4
Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier)This trial tested bapineuzumab, an infused antibody designed to bind and clear beta amyloid from the brain, against a placebo. It measured whether it helped…
CompletedPhase 3NCT00574132Drug trial for diagnosed APOE4 carriers
Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Carrier)This trial tested whether bapineuzumab, an antibody given by infusion that helps clear beta amyloid from the brain, could affect thinking and daily function in…
CompletedPhase 3NCT00575055Carriers enrolled, but higher ARIA risk
A Study to Evaluate Safety, Tolerability, and Efficacy of Lecanemab in Subjects With Early Alzheimer's DiseaseThis Phase 2 trial tested lecanemab, an anti-amyloid antibody given by infusion, in people with early Alzheimer's disease — either mild cognitive impairment or…
CompletedPhase 2NCT01767311Built exclusively for APOE 4/4 carriers
A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's DiseaseThis trial tested two investigational drugs, CAD106 (a vaccine-like immunotherapy targeting amyloid) and CNP520 (a small molecule targeting amyloid…
TerminatedPhase 2NCT02565511Built specifically for APOE4 carriers
A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's DiseaseThis trial tested CNP520, a drug designed to reduce amyloid buildup in the brain, against a placebo in cognitively normal older adults at elevated risk for…
TerminatedPhase 2NCT03131453Open to carriers, but ARIA risk elevated
A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's DiseaseThis Phase 3 trial tests lecanemab, an intravenous and subcutaneous antibody drug, against placebo in people with early Alzheimer's disease — either mild…
ActivePhase 3NCT03887455Directly recruits APOE4 carriers
Effects of Nicotinamide Riboside on Bioenergetics and Oxidative Stress in Mild Cognitive Impairment/Alzheimer's DementiaThis early-phase trial is testing nicotinamide riboside, a form of vitamin B3, in people who already have mild cognitive impairment or mild Alzheimer's…
CompletedEarly Phase 1NCT04430517APOE4 carriers explicitly welcomed
AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate AmyloidThis Phase 3 trial is testing lecanemab, an anti-amyloid antibody drug, in people who are cognitively normal but have early amyloid buildup in their brains —…
ActivePhase 3NCT04468659Built exclusively for APOE4/4 carriers
An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD SubjectsThis Phase 3 trial is testing ALZ-801, an oral drug designed to reduce toxic amyloid clusters in the brain, against a placebo in people with early Alzheimer's…
CompletedPhase 3NCT04770220Requires at least one APOE4 allele
Passive Sensor Identification of Digital Biomarkers to Assess Effects of Orally Administered Nicotinamide RibosideThis trial is testing whether a supplement called nicotinamide riboside (a form of vitamin B3) produces measurable changes in brain energy metabolism in people…
RecruitingNCT05245903APOE4/4 only, closed to new enrollees
Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD SubjectsThis is a long-term extension of a Phase 3 trial testing ALZ-801, an oral drug designed to reduce toxic amyloid clumps in the brain. Researchers are tracking…
TerminatedPhase 3NCT06304883Drug trial for symptomatic early Alzheimer's
A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)This trial tests sabirnetug, an antibody given by IV infusion every four weeks, against placebo. It looks at whether the drug slows decline in thinking and…
ActivePhase 2NCT063351734/4 carriers excluded, one copy may qualify
A Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheimer's DiseaseThis Phase 2 trial is testing SAR448851, a once-daily oral pill, in people with early Alzheimer's disease who have confirmed amyloid buildup in the brain.…
RecruitingPhase 2NCT07688213General AD trial, no APOE4 focus
Brain Imaging Study Of Rosiglitazone Efficacy And Safety In Alzheimer's DiseaseThis Phase 2 trial tested rosiglitazone, a drug originally developed for type 2 diabetes, against a placebo in people with mild to moderate Alzheimer's…
CompletedPhase 2NCT00265148APOE4 enrolled, response may differ
Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's DiseaseThis Phase 3 trial tested rosiglitazone, a diabetes drug, as an add-on to standard Alzheimer's medications like Aricept in people with mild to moderate…
CompletedPhase 3NCT00348140Drug trial, genotype not specified in source
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease PatientsThis trial tested bapineuzumab, an antibody drug given by infusion, against a placebo in people with mild to moderate Alzheimer's. It looked at how well the…
TerminatedPhase 3NCT00667810Drug trial, not APOE4-specific, carriers at risk
Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease PatientsThis trial tested bapineuzumab, an antibody drug given by infusion, against a placebo in people with mild to moderate Alzheimer's. Researchers measured safety…
TerminatedPhase 3NCT00676143Rare inherited mutation families, not APOE4
Dominantly Inherited Alzheimer Network (DIAN)This is an observational study, meaning no drug or treatment is given. Researchers follow families with a rare inherited gene mutation that causes Alzheimer's,…
RecruitingNCT00869817Drug extension study, prior participants only
A Long-Term Safety And Tolerability Extension Study Of Bapineuzumab In Alzheimer Disease PatientsThis trial looked at the long-term safety and tolerability of bapineuzumab, an antibody drug given by infusion, in people with Alzheimer's who had finished an…
TerminatedPhase 3NCT00998764Cancer trial, not for healthy carriers
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain MetastasesThis trial tests whether a more precise form of whole-brain radiation can spare the hippocampus, the brain's memory center, in people whose cancer has spread…
CompletedPhase 2NCT01227954Huntington's study, not about APOE4
Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease CohortEnroll-HD is an observational study, meaning no drug or treatment is given. It follows people with Huntington's disease, and their relatives and controls,…
RecruitingNCT01574053Not Alzheimer's, not APOE4-specific
Natural History Study of SynucleinopathiesThis is an observational study, not a drug test. Researchers follow people with synucleinopathies, such as Parkinson disease, Lewy body dementia, and multiple…
RecruitingNCT01799915Amyloid-focused, drug did not succeed
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory LossThis Phase 3 trial tested solanezumab, an antibody drug given by IV infusion, in cognitively normal older adults who already had amyloid buildup in their…
CompletedPhase 3NCT02008357Open to carriers, not 4-specific
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's DiseaseThis trial tested lanabecestat, a BACE inhibitor drug designed to reduce amyloid production in the brain, against a placebo over two years in people with early…
TerminatedPhase 2NCT02245737Imaging study, genotype not considered
PET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, and Other Neurological and Neuropsychiatric DiseasesThis Phase 1 study uses specialized PET brain scans to look for microglial activation — a sign of brain inflammation — in people with multiple sclerosis and…
RecruitingPhase 1NCT02649985Discontinued trial, not APOE4-specific
A Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease DementiaThis Phase 3 trial tested lanabecestat, a BACE inhibitor drug designed to reduce amyloid production in the brain, in people with early Alzheimer's dementia. It…
TerminatedPhase 3NCT02972658Unrelated to APOE4 or Alzheimer's
Gait Analysis in Neurological DiseaseThis study is analyzing how people with Parkinson's disease and related movement disorders walk at different speeds. Researchers want to identify gait patterns…
ActiveNCT02994719Unrelated to APOE4 or Alzheimer's
The Myelin Disorders Biorepository ProjectThis is a biorepository project, not a treatment trial. Researchers are collecting medical records and biological samples (like blood or tissue) from people…
RecruitingNCT03047369Open to carriers, not 4-specific
Escitalopram for Agitation in Alzheimer's DiseaseThis Phase 3 trial is testing whether escitalopram, a common antidepressant, can safely reduce agitation in people who already have Alzheimer's dementia. Phase…
ActivePhase 3NCT03108846Open to carriers, not 4-specific
Longitudinal Early-onset Alzheimer's Disease Study ProtocolLEADS is an observational study, not a treatment trial. Researchers are tracking how early-onset Alzheimer's and related conditions progress over time in…
ActiveNCT03507257Open to carriers, not 4-specific
Multi-Center Study of Sensory Stimulation to Improve Brain FunctionThis trial tests a device called the GammaSense Stimulation System, which delivers sensory stimulation at a specific brain rhythm frequency called gamma.…
ActiveObservationalNCT03556280Diagnostic test study, not APOE4-specific
Multi-Center Development of a Novel Diagnostic Test for Alzheimer's DiseaseThis study is testing whether a single injection of pramlintide, a diabetes drug already approved by the FDA, can power a blood test for early Alzheimer's.…
ActiveEarly Phase 1NCT03560960Lifestyle study, genotype not required
The Brain Health Champion StudyThis trial tests whether more frequent, personalized coaching on brain-healthy habits produces better follow-through than standard doctor advice alone.…
ActiveObservationalNCT03772977Open to carriers, genotype ignored
Sleep-dependent Learning in AgingThis study is exploring how sleep helps the brain consolidate memories, and whether age-related memory problems are tied to changes in sleep, changes in memory…
RecruitingObservationalNCT03840083Not APOE4-related, movement disorder focus
Trial of Parkinson's And Zoledronic AcidThis trial is testing whether a single IV infusion of zoledronic acid, a bone-strengthening drug already approved for osteoporosis, can reduce fractures in…
CompletedPhase 4NCT03924414Late-stage dementia care, not prevention
Electroconvulsive Therapy (ECT) for Agitation in Dementia (AD)This trial is testing whether electroconvulsive therapy (ECT) — brief, controlled electrical stimulation of the brain — can safely reduce severe agitation in…
CompletedObservationalNCT03926520Open to carriers, genotype not tracked
High Frequency Light and Sound Stimulation to Improve Brain Functions in Alzheimer's DiseaseThis trial tests a device that delivers flickering light and rhythmic sound at 40 Hz to stimulate brain activity in people with mild Alzheimer's disease.…
ActiveObservationalNCT04042922Device trial, carriers not excluded
Daily Light and Sound Stimulation to Improve Brain Functions in Alzheimer's DiseaseThis trial is testing whether daily exposure to flickering light and pulsed sound at a specific frequency (40 Hz, known as gamma stimulation) can improve brain…
ActiveObservationalNCT04055376Symptom trial, not APOE4-specific
Cannabidiol Solution for the Treatment of Behavioral Symptoms in Older Adults With Mild Cognitive Impairment or Alzheimer's DementiaThis trial tests a cannabis-derived mouth solution, high in CBD and low in THC, in people with mild cognitive impairment or mild to moderate Alzheimer's. It…
ActiveEarly Phase 1NCT04075435Open to carriers, genotype not tracked
Metformin in Alzheimer's Dementia PreventionThis trial is testing whether extended-release metformin, a widely used diabetes drug, can slow memory decline in people who are overweight and already showing…
ActivePhase 2NCT04098666Observational study, genotype not considered
Contributions of mTBI to Neurodegeneration Due to Chronic Traumatic Encephalopathy (CTE) and Alzheimer's Disease (AD)This observational study is not testing a treatment. It is using EEG brain scans, MRIs, blood draws, and spinal fluid samples to study whether Veterans who…
RecruitingNCT04124029Not relevant to APOE4 carriers
Trial-Ready Cohort-Down Syndrome (TRC-DS)This is not a treatment trial. It is a study building a pool of adults with Down syndrome, ages 25 to 55, who are ready to be recruited into future Alzheimer's…
RecruitingNCT04165109Open to carriers, not 4-specific
Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older AdultsPREVENTABLE is a large Phase 4 trial testing whether atorvastatin 40 mg — a common cholesterol-lowering statin — can reduce the combined risk of death,…
RecruitingPhase 4NCT04262206Not Alzheimer's-related; no APOE4 relevance
Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to DaratumumabThis trial tests a three-drug combination (daratumumab, pomalidomide, and dexamethasone) in people with AL amyloidosis whose disease came back or stopped…
ActivePhase 2NCT04270175Open to carriers, genotype not tracked
Individualized Brain Stimulation to Improve Mobility in Alzheimer's DiseaseThis pilot trial is testing whether a personalized form of transcranial direct current stimulation (tDCS) — a non-invasive technique that delivers a mild…
ActiveObservationalNCT04289402FTLD-focused, not APOE4-relevant
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)This is a large North American research registry and natural history study tracking people with frontotemporal lobar degeneration (FTLD) and related conditions…
RecruitingNCT04363684Wrong condition, not APOE4-relevant
Phase 1/2 Clinical Trial of LY3884963 in Patients With Frontotemporal Dementia With Progranulin Mutations (FTD-GRN)This trial is testing LY3884963, a biological therapy delivered directly into the fluid around the brain and spine, in people who have frontotemporal dementia…
ActivePhase 1NCT04408625High ARIA risk for carriers
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)This Phase 3 trial tested donanemab, an anti-amyloid antibody drug, against placebo in people with early Alzheimer's disease. Researchers measured how well it…
ActivePhase 3NCT04437511Not APOE4-related; FTD gene families only
Neurofilament Surveillance Project (NSP)This is a blood-collection study, not a drug test. Researchers are measuring neurofilament, a protein that can signal nerve cell damage, in people from…
ActiveNCT04516499Not Alzheimer's-focused, genotype not mentioned
Remote Monitoring in Progressive Supranuclear Palsy (PSP)This study tests no drug. It watches how wearable sensors and remote digital tools track falls, movement, speech, and thinking in people with progressive…
Not yet recruitingNCT04753320
Copy a forum-ready post
Keep exploring
Educational, not medical advice. Trial decisions belong between you and your physician.